$5.09 $0.10 (2.0%)

04:30 PM EDT on 07/06/20

Seres Therapeutics (NASDAQ:MCRB)

CAPS Rating: 5 out of 5

Current Price $5.09 Mkt Cap $369.5M
Open $5.13 P/E Ratio 0.00
Prev. Close $5.09 Div. (Yield) $0.00 (0.0%)
Daily Range $5.01 - $5.52 Volume 1,168,303
52-Wk Range $2.15 - $6.59 Avg. Daily Vol. 583,255

Caps

How do you think NASDAQ:MCRB will perform against the market?

Add Stock to CAPS Watchlist

All Players

20 Outperform
0 Underperform
 

All-Star Players

7 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:MCRB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (99.03)
Submitted July 07, 2015

I was hoping CAPS would have Seres ratable on the day of their ridiculous IPO, when the shares were priced at 18, opened at 29, and rose to 51. Alas, as far as MF was concerned, MCRB meant McRib and I didn't feel like shorting fast food. Seres is… More

NASDAQ:MCRB VS S&P 500 (SPY)

NASDAQ:MCRB Summary

Fools bullish on NASDAQ:MCRB are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about MCRB.

Recs

0
Member Avatar DaytradingStars (85.18) Submitted: 5/30/2020 7:16:04 AM : Outperform Start Price: $5.42 NASDAQ:MCRB Score: -10.15

SS10

Recs

0
Member Avatar MujamMojam (< 20) Submitted: 1/16/2020 1:11:24 AM : Outperform Start Price: $3.05 NASDAQ:MCRB Score: +70.72

Seres Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.33, a 155.5% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15 price target.

https://theenterpriseleader.com/2019/11/24/seres-therapeutics-nasdaqmcrb-earns-buy-rating-from-hc-wainwright.html

..Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. The firm had revenue of $7.03 million during the quarter, compared to analyst estimates of $6.69 million. On average, sell-side analysts forecast that Seres Therapeutics will post -1.43 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nikko Asset Management Americas Inc. grew its position in Seres Therapeutics by 58.2% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 7,661,963 shares of the biotechnology company’s stock worth $30,724,000 after purchasing an additional 2,818,889 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in Seres Therapeutics by 58.2% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,661,963 shares of the biotechnology company’s stock worth $30,724,000 after purchasing an additional 2,818,889 shares during the last quarter. ARK Investment Management LLC grew its position in Seres Therapeutics by 33.1% in the 2nd quarter. ARK Investment Management LLC now owns 7,038,885 shares of the biotechnology company’s stock worth $22,665,000 after purchasing an additional 1,751,172 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in Seres Therapeutics in the 2nd quarter worth $8,050,000. Finally, BlackRock Inc. grew its position in Seres Therapeutics by 5.6% in the 2nd quarter. BlackRock Inc. now owns 2,323,332 shares of the biotechnology company’s stock worth $7,480,000 after purchasing an additional 122,803 shares during the last quarter. Institutional investors own 98.37% of the company’s stock.

Leaderboard

Find the members with the highest scoring picks in MCRB.

Score Leader

MujamMojam

MujamMojam (< 20) Score: +70.72

The Score Leader is the player with the highest score across all their picks in MCRB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MujamMojam < 20 1/16/2020 Outperform 3Y $3.05 +66.89% -3.83% +70.72 1 Comment
jeepdrew222 82.84 12/30/2019 Outperform 5Y $4.05 +25.68% -1.85% +27.53 0 Comment
OLDDOG55 < 20 5/12/2020 Outperform 3Y $4.65 +9.46% +7.82% +1.64 0 Comment
andjoy 94.07 6/23/2020 Outperform 5Y $5.07 +0.39% +1.10% -0.70 0 Comment
DaytradingStars 85.18 5/29/2020 Outperform 5Y $5.42 -6.00% +4.15% -10.15 1 Comment
jacksonhole72 65.04 2/28/2019 Outperform 1Y $6.14 -17.15% +13.51% -30.66 0 Comment
jcder 38.66 4/9/2019 Outperform 5Y $6.58 -22.64% +10.25% -32.89 0 Comment
jck444 96.58 1/29/2018 Outperform 5Y $10.97 -53.60% +10.86% -64.46 0 Comment
hyperionives 83.05 11/16/2017 Outperform 5Y $9.23 -44.85% +23.09% -67.94 0 Comment
portefeuille3 97.84 12/27/2017 Outperform 5Y $10.35 -50.82% +18.53% -69.36 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MCRB.